



## Anand Mehta

Partner

One World Center  
10<sup>th</sup> & 13<sup>th</sup> Floors, Tower 1C  
841 Senapati Bapat Marg  
Mumbai 400 013  
India

T: +91 98200 76600  
E: [anand.mehta@khaitanco.com](mailto:anand.mehta@khaitanco.com)

### Practices:

Corporate & Commercial  
Mergers & Acquisitions  
Data Privacy  
Employment  
White Collar Crime

### Education:

LL.B., University of Mumbai  
(1989)  
C.S, Institute of Company  
Secretaries of India (1997)

### Professional Affiliations:

Bar Council of Maharashtra &  
Goa  
Institute of Company Secretaries  
of India

### Sectors:

Pharmaceuticals and Healthcare

Anand Mehta is a Partner in the Corporate and Commercial Practice group in the Mumbai office. He specializes in corporate acquisitions and mergers, India entry strategies, corporate & commercial laws and contract laws.

Over the years, Anand has assisted several clients including some Fortune 500 companies to establish and expand their India operations including forming joint ventures and other strategic alliances. He has actively participated in commercial negotiations for several multinational clients.

Anand advises clients in relation to employment, data privacy and other corporate fraud issues / white collar crimes issues from a preventive and compliance perspective. He helps clients conduct training sessions, supporting pre-investigation of employee investigation etc.

### Representative Matters:

In his area of expertise, Anand has advised and represented clients which include:

- **IHH Healthcare Berhad**, on its US\$ 1.2 billion takeover of Fortis Healthcare Limited comprising of a primary infusion and consequent open offers at Fortis as well as its listed subsidiary, Fortis Malar Hospital Limited;
- **Parkway Pantai Limited**, a subsidiary of IHH Healthcare Berhad, on (i) its US\$ 194 million investment in RGE Medical Associates comprising of a primary equity infusion and secondary purchases from multiple exiting financial investors and some stake sold by the promoters; (ii) its proposed US\$ 60 million acquisition of the stake of its Indian partner in its greenfield hospital joint venture; and (iii) the proposed transfer of its entire stake (50% of the share capital of the JV Company) to the JV partner- Apollo Hospitals Enterprises Ltd. (AHEL), pursuant to which the JV Company - Apollo Gleneagles Hospitals Ltd. has become the wholly owned subsidiary of AHEL;
- **IHH Healthcare Berhad Ltd and SRL** on structuring and negotiating the revised exit rights of current PE investors. Also advised on certain corporate matters of SRL Diagnostics;
- Several **medical devices and pharmaceutical companies** on their M&A, corporate, advisory and commercial contract;
- **Robotic Wares Private Limited**, which runs the logistics platform FarEye (and its investor Deutsche Post DHL Group) on its acquisition of the business of freight logistics

marketplace Dipper Technologies in a cash and stock transaction;

- A major **German conglomerate** on its investment in an Indian company involved in development of software for the logistics sector;
- **Nomura Research Institute, Limited**, on its strategic Indian outsourcing joint venture with Nomura, Inc.;
- **Amiad Filtration Systems (India) Private Limited** leading global producer of filtration products headquartered in Israel, and its wholly owned Singapore, Filtration Control Systems Pte. Ltd., on: (a) buy-out of the entire stake of its erstwhile joint venture partner, in Amiad Filtration Systems (India) Private Limited; and (b) sale of its entire stake in JSK Engg. Private Limited to its joint venture partner;
- **Akorn Inc** on (i) acquisition of certain assets of Kilitch Drugs (India) Ltd, as well as certain assets of NBZ Pharma Limited, for approximately USD 52 million in cash and future contingent payments totaling up to approximately USD 6 million; and (ii) exiting its business from India by selling its equity stake in Akorn India to another acquirer.
- **Olam International Limited** on acquisition of bulk **spices** and private label assets and businesses in India, Vietnam and US of Vallabhadas Kanji Limited for USD 18 million;
- **Dosch Pharmaceuticals Private Limited** on sale of its animal health division to Sanofi Synthelabo (India) Limited for, creating a market entry for Merial (Animal Health division of Sanofi) in India;
- **Bajaj Corp Limited** on acquisition of the entire intangible assets, including the trademarks of "NOMARKS" brand from Ozone Ayurvedics, India and Ozone UK Limited;
- **Spectro Analytical Labs limited (Spectro)** and its promoters on the sale of a 60% stake in Spectro to Eurofins Environment Testing Lux Holding SARL (Eurofins) through a mix of primary and secondary acquisitions; and
- **Astral Poly Technik Limited (Astral)**, a listed company, on its acquisition of 51% stake in Rex Polyextrusion Private Limited (Rex) for a consideration of INR 75.2 crores and subsequent amalgamation of Rex into Astral.

### Publications and Presentations:

- Authored an article with colleagues on "**Health Care M&A Transactions in India**" for the "Health Care Mergers and Acquisitions Answer Book (2021 Edition)" published by Practising Law Institute in their 2021 Edition;
- Conducted a webinar on healthcare webinar titled "**Next Wave of Growth in Indian Healthcare**" with Nathealth;
- Anand often attends as a speaker / panelist / judge at conferences / seminars and law school moot court competitions. More recently, he has spoken at several forums on the new Companies Act;



**KHAITAN  
&CO**

*Advocates since 1911*

- Anand has conducted webinars on the topics like “**Cross-Border Data Privacy and Security Best Practices**” and “**Overview of the Data Protection and Privacy Regime in India**”; and
- He has authored several articles for international journals on Indian laws.

### **Recognitions and Accomplishments:**

Anand has been acknowledged for his experience and expertise by:

- **IFLR 1000 lawyer** rankings 2020 as a Notable Practitioner in M&A transactions.